Based on these observations, and prompted by a study showing that the combined treatment with Cy, Tα1, and IL-2 was superior to the single agents, or the combination of Cy with either Tα1 or IL-2, in improving survival of mice with LLC (24), a phase II study with metastatic melanoma patients treated with dacarbazine, Tα1 and IL-2 was performed (25). The gene discussed is IL2; the disease is metastatic melanoma.